{"id":"glargine-and-humalog","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"rare to uncommon","effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glargine (insulin glargine) is a long-acting insulin analog that binds to insulin receptors to promote glucose uptake and storage, providing basal insulin coverage over 24 hours. Humalog (insulin lispro) is a rapid-acting insulin analog that quickly lowers postprandial (after-meal) blood glucose by enhancing cellular glucose uptake. Together, they mimic physiologic insulin secretion with basal-bolus dosing.","oneSentence":"Glargine is a long-acting basal insulin that provides steady glucose control, while Humalog is a rapid-acting insulin that covers mealtime glucose spikes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:08.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT07171684","phase":"NA","title":"Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-11-26","conditions":"Diabetes in Pregnancy, Gestational Diabetes","enrollment":176},{"nctId":"NCT06370715","phase":"PHASE4","title":"A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-18","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT06419803","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT06419777","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT04537923","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-19","conditions":"Type 2 Diabetes","enrollment":1428},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT05373186","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT05579119","phase":"PHASE4","title":"SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)","status":"COMPLETED","sponsor":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social","startDate":"2022-07-06","conditions":"Type 2 Diabetes","enrollment":76},{"nctId":"NCT05373199","phase":"PHASE1","title":"A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT02227862","phase":"PHASE3","title":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-06","conditions":"Type 1 Diabetes","enrollment":558},{"nctId":"NCT02666430","phase":"PHASE3","title":"Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-12","conditions":"Type 1 Diabetes Mellitus","enrollment":127},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT03328845","phase":"PHASE4","title":"Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2017-01-20","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT03350984","phase":"PHASE4","title":"Insulin Schemes for Type 2 Diabetes Control","status":"COMPLETED","sponsor":"Universidad de Guanajuato","startDate":"2017-11-02","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT03670641","phase":"PHASE4","title":"Remission Through Early Monitored Insulin Therapy - Duration Month","status":"COMPLETED","sponsor":"Sandra Sobel","startDate":"2019-03-26","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT02250794","phase":"PHASE4","title":"Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2014-10","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT04157738","phase":"PHASE4","title":"A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-27","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":24},{"nctId":"NCT01269034","phase":"PHASE4","title":"New Onset Type 1 Diabetes: Role of Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40},{"nctId":"NCT03338023","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-23","conditions":"Type 1 Diabetes","enrollment":272},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT04484779","phase":"NA","title":"A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-14","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":67},{"nctId":"NCT04690309","phase":"PHASE4","title":"Human Versus Analogue Insulin in Patients After Pancreatectomy.","status":"UNKNOWN","sponsor":"Polish Society of Diabetology","startDate":"2018-07-01","conditions":"Pancreatogenous Diabetes","enrollment":100},{"nctId":"NCT02229227","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":814},{"nctId":"NCT02192424","phase":"PHASE3","title":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":109},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03214367","phase":"PHASE3","title":"A Study of LY900014 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-17","conditions":"Type 1 Diabetes Mellitus","enrollment":1392},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT02690883","phase":"PHASE4","title":"Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-04-08","conditions":"Diabetic Nephropathies","enrollment":92},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT03170544","phase":"PHASE1","title":"Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-08-16","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT01621178","phase":"PHASE3","title":"A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes, Chronic Kidney Disease","enrollment":577},{"nctId":"NCT02152384","phase":"PHASE1","title":"A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-06","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT00505882","phase":"PHASE4","title":"Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01378117","phase":"PHASE4","title":"Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-08","conditions":"Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia","enrollment":90},{"nctId":"NCT02197520","phase":"PHASE1","title":"A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01755468","phase":"PHASE3","title":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT02741687","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-06","conditions":"Hyperglycemia","enrollment":80},{"nctId":"NCT01184014","phase":"PHASE4","title":"Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2010-08","conditions":"Hyperglycemia","enrollment":72},{"nctId":"NCT02012465","phase":"EARLY_PHASE1","title":"Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-09","conditions":"Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia","enrollment":15},{"nctId":"NCT01468987","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Diabetes Mellitus, Type 2","enrollment":1369},{"nctId":"NCT01481779","phase":"PHASE3","title":"A Study in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 1","enrollment":455},{"nctId":"NCT01454284","phase":"PHASE3","title":"A Study in Participants With Type I Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 1","enrollment":1114},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02443402","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT02294474","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":505},{"nctId":"NCT02273180","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-10","conditions":"Type 1 Diabetes Mellitus","enrollment":507},{"nctId":"NCT02451917","phase":"PHASE4","title":"Glargine Versus NPH in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":34},{"nctId":"NCT02189395","phase":"PHASE4","title":"Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting","status":"TERMINATED","sponsor":"Riverside University Health System Medical Center","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":52},{"nctId":"NCT00574405","phase":"NA","title":"Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy","status":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2005-04","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT02915250","phase":"PHASE1","title":"A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2016-10","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT02811484","phase":"PHASE4","title":"Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01810952","phase":"PHASE4","title":"The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-09","conditions":"Hyperglycemia, Diabetes Mellitus","enrollment":37},{"nctId":"NCT00976391","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":586},{"nctId":"NCT00652288","phase":"PHASE1","title":"Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-04","conditions":"Diabetes Mellitus, Type I","enrollment":36},{"nctId":"NCT00115570","phase":"PHASE3","title":"Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-04","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":572},{"nctId":"NCT00468754","phase":"NA","title":"A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-07","conditions":"Diabetes Mellitus Type 1","enrollment":50},{"nctId":"NCT02514850","phase":"PHASE1","title":"A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02526810","phase":"PHASE4","title":"Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT01000922","phase":"PHASE2","title":"A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro","status":"COMPLETED","sponsor":"Biodel","startDate":"2006-06","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT00467649","phase":"PHASE4","title":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT00960661","phase":"PHASE3","title":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1036},{"nctId":"NCT02155023","phase":"NA","title":"Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2014-01","conditions":"Diabetes","enrollment":8},{"nctId":"NCT00927524","phase":"NA","title":"Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-04","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT00700622","phase":"PHASE3","title":"Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks","status":"TERMINATED","sponsor":"Mannkind Corporation","startDate":"2008-05","conditions":"Diabetes, Type 1","enrollment":130},{"nctId":"NCT01421147","phase":"PHASE3","title":"A Study in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 1","enrollment":536},{"nctId":"NCT01191268","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 2","enrollment":884},{"nctId":"NCT00883558","phase":"PHASE2","title":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT01215955","phase":"PHASE4","title":"Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":1117},{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01121835","phase":"PHASE4","title":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":934},{"nctId":"NCT01136746","phase":"PHASE3","title":"Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Hyperglycemia","enrollment":16},{"nctId":"NCT00993473","phase":"PHASE3","title":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 1 Diabetes Mellitus","enrollment":125},{"nctId":"NCT00540709","phase":"PHASE4","title":"PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-11","conditions":"Diabetes Mellitus","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"glargine and humalog","genericName":"glargine and humalog","companyName":"Riverside University Health System Medical Center","companyId":"riverside-university-health-system-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glargine is a long-acting basal insulin that provides steady glucose control, while Humalog is a rapid-acting insulin that covers mealtime glucose spikes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}